Cargando…

Prognostic Performance of Metabolic Indexes in Predicting Onset of Type 1 Diabetes

OBJECTIVE: In this investigation we evaluated nine metabolic indexes from intravenous glucose tolerance tests (IVGTTs) and oral glucose tolerance tests (OGTTs) in an effort to determine their prognostic performance in predicting the development of type 1 diabetes in those with moderate risk, as defi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Ping, Wu, Yougui, Zhu, Yiliang, Dagne, Getachew, Johnson, Giffe, Cuthbertson, David, Krischer, Jeffrey P., Sosenko, Jay M., Skyler, Jay S.
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2010
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992179/ https://www.ncbi.nlm.nih.gov/pubmed/20807869 http://dx.doi.org/10.2337/dc10-0802

Ejemplares similares

Prognostic Accuracy of Immunologic and Metabolic Markers for Type 1 Diabetes in a High-Risk Population: Receiver operating characteristic analysis
por: Xu, Ping, et al.
Publicado: (2012)

Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2008)

Trends of Earlier and Later Responses of C-peptide to Oral Glucose Challenges With Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants
por: Sosenko, Jay M., et al.
Publicado: (2010)

Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
por: Orban, Tihamer, et al.
Publicado: (2009)

A Longitudinal Study of GAD65 and ICA512 Autoantibodies During the Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 (DPT-1) Participants
por: Sosenko, Jay M., et al.
Publicado: (2011)

Incident Dysglycemia and Progression to Type 1 Diabetes Among Participants in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2009)

Progression to Diabetes in Relatives of Type 1 Diabetic Patients: Mechanisms and Mode of Onset
por: Ferrannini, Ele, et al.
Publicado: (2010)

Glucose Excursions Between States of Glycemia With Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1)
por: Sosenko, Jay M., et al.
Publicado: (2010)

The Application of the Diabetes Prevention Trial–Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes
por: Sosenko, Jay M., et al.
Publicado: (2012)

Erratum. Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care 2011;34:1785–1787
por: Sosenko, Jay M., et al.
Publicado: (2018)

Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study
por: Sosenko, Jay M., et al.
Publicado: (2011)

The Metabolic Progression to Type 1 Diabetes as Indicated by Serial Oral Glucose Tolerance Testing in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2012)

Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the Risk Classification of Type 1 Diabetes
por: Sosenko, Jay M., et al.
Publicado: (2014)

The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation Into an Autoantibody Risk Score in Relatives of Type 1 Diabetic Patients
por: Sosenko, Jay M., et al.
Publicado: (2013)

Acceleration of the Loss of the First-Phase Insulin Response During the Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants
por: Sosenko, Jay M., et al.
Publicado: (2013)

The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes
por: Sims, Emily K., et al.
Publicado: (2021)

Development of Autoantibodies in the TrialNet Natural History Study
por: Vehik, Kendra, et al.
Publicado: (2011)

Zinc Transporter-8 Autoantibodies Improve Prediction of Type 1 Diabetes in Relatives Positive for the Standard Biochemical Autoantibodies
por: Yu, Liping, et al.
Publicado: (2012)

A New Approach for Diagnosing Type 1 Diabetes in Autoantibody-Positive Individuals Based on Prediction and Natural History
por: Sosenko, Jay M., et al.
Publicado: (2015)

Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials
por: Nathan, Brandon M., et al.
Publicado: (2017)

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association
por: Insel, Richard A., et al.
Publicado: (2015)

Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials
por: Sosenko, Jay M., et al.
Publicado: (2020)

Distribution of C-Peptide and Its Determinants in North American Children at Risk for Type 1 Diabetes
por: Xu, Ping, et al.
Publicado: (2014)

Islet Autoantibody Seroconversion in the DPT-1 Study: Justification for repeat screening throughout childhood
por: Vehik, Kendra, et al.
Publicado: (2011)

The Compelling Case for Anti-CD3 in Type 1 Diabetes
por: Skyler, Jay S.
Publicado: (2013)

A quantitative measure of treatment response in recent‐onset type 1 diabetes
por: Bundy, Brian N., et al.
Publicado: (2020)

Stopping Type 1 Diabetes: Attempts to Prevent or Cure Type 1 Diabetes in Man
por: Skyler, Jay S., et al.
Publicado: (2011)

George S. Eisenbarth: Insulin and Type 1 Diabetes
por: Pugliese, Alberto, et al.
Publicado: (2013)

Type 1 Diabetes at a Crossroads!
por: Cefalu, William T., et al.
Publicado: (2015)

Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment
por: Orban, Tihamer, et al.
Publicado: (2014)

Occupational health surveillance: Pulmonary function testing in emergency responders
por: McCluskey, James D., et al.
Publicado: (2014)

Performance of HbA(1c) as an Early Diagnostic Indicator of Type 1 Diabetes in Children and Youth
por: Vehik, Kendra, et al.
Publicado: (2012)

Long-Term Outcome of Individuals Treated With Oral Insulin: Diabetes Prevention Trial–Type 1 (DPT-1) oral insulin trial
por: Vehik, Kendra, et al.
Publicado: (2011)

Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis
por: Skyler, Jay S., et al.
Publicado: (2017)

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data
por: Greenbaum, Carla J., et al.
Publicado: (2012)

Diabetic Neuropathy: A Position Statement by the American Diabetes Association
por: Pop-Busui, Rodica, et al.
Publicado: (2017)

TCF7L2 Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes
por: Redondo, Maria J., et al.
Publicado: (2018)

A Rule-Based Prognostic Model for Type 1 Diabetes by Identifying and Synthesizing Baseline Profile Patterns
por: Lin, Ying, et al.
Publicado: (2014)

Failure to Preserve β-Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New- Onset Type 1 Diabetes
por: Gottlieb, Peter A., et al.
Publicado: (2010)

“Pressured to prescribe” The impact of economic and regulatory factors on South-Eastern ED physicians when managing the drug seeking patient
por: Kelly, Sharon, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_toflk5drlvh5e6h62g510nh9mq